Saturday, 31 October 2026European Markets

AERKOMM INC Skyrockets 26% On Friday: What's Driving The Surge?

Loading stream...

(vianews) - investors responded positively to aerkomm inc (cac 40: akom.pa), as its shares surged by 26.13% to eur2.80 during friday's trading session - marking an encouraging turnaround after five consecutive losses in previous sessions. meanwhile, the cac 40 index also advanced, rising 0.68% to eur7,640.68 to suggest potential reversal of any downward trends observed previously and suggesting an up trend trading session overall.

about aerkomm inc

aerkomm inc. is an award-winning provider of in-flight entertainment and connectivity solutions in the asian pacific region, providing services such as wi-fi, cellular phones, movies, gaming, live tv and music through built-in inflight entertainment systems or passenger's personal devices. aerkomm also offers content management services and e-commerce solutions along with their aerkomm k++ advanced ifec system - founded in 2013 and headquartered in fremont california with operations spread throughout southeast asia and other regions where passengers travel more. aerkomm is dedicated to improving air travel experiences across asia-pacific passengers in every way possible!

equity analysis

over the past year, aerkomm inc has experienced negative earnings per share (eps) of eur-1.35 indicating it may be facing financial difficulty and may no longer be producing profits.

more news about aerkomm inc (akom.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com